Back to top
more

Inogen (INGN)

(Real Time Quote from BATS)

$6.25 USD

6.25
59,348

-0.08 (-1.26%)

Updated Aug 6, 2025 10:50 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (148 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Inogen Gains From Commercial Launch of Wireless Connect

by Zacks Equity Research

Inogen's (INGN) expanding product portfolio lends it a competitive edge in the respiratory care devices market.

Zacks Equity Research

Why Is Inogen (INGN) Down 7.9% Since Last Earnings Report?

by Zacks Equity Research

Inogen (INGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Inogen (INGN) Q3 Earnings Beat, 2018 Revenue Guidance Up

by Zacks Equity Research

Inogen (INGN) gains from solid direct-to-consumer revenues in Q3; 2018 view up.

Zacks Equity Research

Omnicell (OMCL) Hits Fresh High: Is There Still Room to Run?

by Zacks Equity Research

Omnicell (OMCL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Equity Research

Is Inogen (INGN) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Is (INGN) Outperforming Other Medical Stocks This Year?

Zacks Equity Research

Inogen (INGN) Surpasses Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Inogen (INGN) delivered earnings and revenue surprises of 40.38% and 4.62%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

Panel Of Zacks Experts headshot

Top Stock Picks for the Week of November 5th

by Panel Of Zacks Experts

Two Companies Outperforming Their Industries.

Zacks Equity Research

Can Solid European Sales Boost Inogen (INGN) in Q3 Earnings?

by Zacks Equity Research

Strong performance in Europe is likely to boost Inogen's (INGN) top line in the third quarter. However, the decline in rental revenues is a concern.

Zacks Equity Research

Integra (IART) Q3 Earnings Meet Estimates, Revenue View Dips

by Zacks Equity Research

Integra LifeSciences' (IART) success with its channel expansion policy and Codman acquisition raise optimism on the stock.

Zacks Equity Research

Inogen (INGN) Gains But Lags Market: What You Should Know

by Zacks Equity Research

Inogen (INGN) closed the most recent trading day at $192.30, moving +0.6% from the previous trading session.

Zacks Equity Research

NuVasive (NUVA) Q3 Earnings Lag Estimates, Revenues Top Mark

by Zacks Equity Research

NuVasive (NUVA) registers balanced growth across its couple of business wings.

Zacks Equity Research

Chemed (CHE) Beats on Q3 Earnings, Raises 2018 Guidance

by Zacks Equity Research

The expansion in adjusted operating margin at Chemed (CHE) raises investor hopes on the stock.

Zacks Equity Research

Inogen (INGN) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Inogen (INGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Cerner's (CERN) Q3 Earnings Match Estimates, Bookings Up Y/Y

by Zacks Equity Research

Cerner (CERN) gains from strong segmental revenues in the third quarter. Guidance for 2018 is impressive.

Zacks Equity Research

Zacks.com featured highlights include: ABIOMED, Inogen, Turtle Beach, MCBC and Rush Enterprises

by Zacks Equity Research

Zacks.com featured highlights include: ABIOMED, Inogen, Turtle Beach, MCBC and Rush Enterprises

Zacks Equity Research

Merit Medical (MMSI) Tops Q3 Earnings & Revenue Estimates

by Zacks Equity Research

Merit Medical (MMSI) gains from solid segmental performance in Q3. Also, the company reiterated its guidance for 2018.

Zacks Equity Research

Stryker (SYK) Beats Q3 Earnings, Misses Sales Estimates

by Zacks Equity Research

Stryker's (SYK) Q3 results benefit from solid segmental performance. Also, the company sustained strength in International sales.

Zacks Equity Research

Varian Medical (VAR) Jumps: Stock Rises 7.7%

by Zacks Equity Research

Varian Medical (VAR) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

Zacks Equity Research

Pick 5 Profitable Stocks With Alluring Net Income Ratio

by Zacks Equity Research

Investors always focus on companies that have a high level of profitability irrespective of the current market scenario.

Zacks Equity Research

McKesson (MCK) Beats Q2 Earnings, Misses Revenue Estimates

by Zacks Equity Research

McKesson's (MCK) Q2 results benefit from solid performance in the Medical-Surgical Solutions segment.

Zacks Equity Research

Varian (VAR) Misses Earnings, Beats Revenue Estimates in Q4

by Zacks Equity Research

Varian's (VAR) Q4 results benefit from strong growth in Oncology Systems. Also, solid guidance boosts investors' optimism.

Zacks Equity Research

Is Inogen (INGN) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Is (INGN) Outperforming Other Medical Stocks This Year?

Zacks Equity Research

Medidata (MDSO) Tops Earnings & Revenue Estimates in Q3

by Zacks Equity Research

Strong performance in the Subscription revenues segment drives Medidata???s (MDSO) results in Q3. Professional services also posted steady growth.

Zacks Equity Research

Intuitive Surgical (ISRG) Beats on Q3 Earnings & Revenues

by Zacks Equity Research

Strong performance in the Instruments & Accessories and Systems segments drive Intuitive Surgical's (ISRG) top line in Q3.

Zacks Equity Research

Abbott (ABT) Q3 Earnings Top Estimates, Guidance Narrowed

by Zacks Equity Research

Within Structural Heart, growth was driven by several product areas across Abbott's (ABT) broad portfolio, including AMPLATZER PFO Occluder and MitraClip.